继发性急性髓系白血病的研究进展  

Advances of secondary acute myeloid leukemia

作　　者：秦嘉琦 程骁赪[1] 周越 刘清 刘俊秀 石晓菁[1] QIN Jiaqi;CHENG Xiaocheng;ZHOU Yue;LIU Qing;LIU Junxiu;SHI Xiaojing(Department of Hematology,the Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou,215001,China)

机构地区：[1]南京医科大学附属苏州医院(苏州市立医院)血液科,江苏苏州215001

出　　处：《临床血液学杂志》2025年第3期247-251,共5页Journal of Clinical Hematology

摘　　要：继发性急性髓系白血病(sAML)包含继发于先前有血液系统肿瘤基础的急性髓系白血病(AHDAML)和有恶性肿瘤放化疗病史的治疗相关性白血病(t-AML)两类。sAML是一类异质性很强的疾病,通常预示着较差的预后,生存期短,治疗方案有限,以阿糖胞苷为基础的传统治疗方案如“7+3”方案总体有效率较低,新的治疗选择亟待突破。本文就近几年对于该病的基础研究和临床进展进行综述。Secondary acute myeloid leukemia(sAML)is defined as AML occurring after an antecedent myeloid disease(AHD-AML)or after exposure to ionizing radiation and/or cytotoxic chemotherapy(t-AML).sAML represents a heterogenous group of patients with inferior prognosis,short survival period and limited treatment options.Standard-of-care therapy with“7+3”would be the most common approach,given a relative low overall response rate.Novel strategies and treatment options have been explored.The progresses will be summarized in this paper.

关 键 词：急性髓系白血病 继发性白血病 治疗 预后 

分 类 号：R733.71[医药卫生—肿瘤]